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1. Introduction
Gangliosides, GSLs, are expressed in the outer leaflet of the plasma membrane of animal cells
and involved in a variety of functions, including serving as antigens, receptors for bacterial
toxins, mediators of cell adhesion, and mediators and modulators of signal transduction.
Moreover, the accumulated lines of evidence have shown that gangliosides play pivotal roles
in cancer metastasis. As the first and simplest member in the metabolic series of the ganglioside
family, GM3 is a metabolic precursor of more complex natural gangliosides, which in turn
determines their contents and biological functions in cells and tissues. GM3 has been demon‐
strated to be involved in regulation of various processes including cell proliferation, differen‐
tiation, apoptosis, embryogenesis and oncogenesis, etc. However, it is difficult to understand
the defined functional concepts of GM3 in cancer metastasis because GM3 indirectly exert their
effects via regulating target genes.
Target  genes indicated in cellular transformation and tumor progression have been div‐
ided into two categories:  proto-oncogenes and tumor suppressor genes.  In cancer,  it  can
thus be speculated that an altered balance of tumor suppressor genes towards proto-on‐
cogenes may contribute to tumor transformation. Alterations in proto-oncogenes and tu‐
mor  suppressor  genes  are  largely  dependent  on  point  mutation,  amplification  or
translocation. Consequently, the normal control mechanisms that constrain the expression
of  genes  are  undermined,  and  thus  the  oncogene  is  continually  expressed,  resulting  in
tumor transformation [1]. Similarly, genetic transformation has been linked to melanoma
genesis and progression. These genes encompass many signaling pathways, including the
RTK,  PI3-K,  Rb,  p53,  Wnt,  and  NF-κB  pathways  [2].  Further  evidence  implicated  the
downstream  oncogenes  of  these  pathways  in  melanoma  ranges  from  Ras,  B-Raf,  Kit,
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Mitf, Cyclin D1, CDK4 to HDM2 [1], [3]. Although genetic discoveries related to melano‐
ma  transformation  have  been  accelerated  greatly  in  recent  years,  the  involvement  of
GM3 in melanoma metastasis  via these proto-oncogenes or  tumor suppressor genes has
not yet been clearly established.
The present chapter was aimed to give insights into the mechanisms that GM3 regulates
melanoma metastasis via its target genes. To keep the discussion focused, we will discuss the
relationship between GM3 contents and their abilities to regulate proto-oncogenes or tumor
suppressor genes, which in turn mediate melanoma metastasis. To screen GM3 target genes,
we obtained cells (CSSH-1) that overexpressed B4galt6 cDNA and cells (CAH-3) that sup‐
pressed its expression, which in turn result in GM3 modulation [4], [5]. In the CSSH-1 cells,
GM3 contents were doubled, but in the CAH-3 cells, GM3 expression was halved compared
with vector transfectant control, SM-1 and CM-1, respectively [4], [5]. To further confirm the
roles of GM3 in melanoma cells, St3gal5 silenced cells were established by transfecting B16
cells with St3gal5 siRNA and it was found that the introduction of St3gal5 siRNA to B16 cells
resulted in GM3 depletion as compared with the scrambled siRNA transfectant control [4], [5].
Moreover, we would elucidate the mechanism that GM3 regulate melanoma metastasis via
the genes, such as Ly-GDI, TNF-α, MMP-9, MMP-2, Caveolin-1 and Plaur, etc. and the
functions of these genes on the phenotypes of melanoma cells, such as invasive proliferation,
adhesion, migration and invasion would be finally addressed based on our and others’
publications (Table 1) [6].
2. Materials and methods
2.1. Cell lines and culture
Murine melanoma B16 cells were kindly provided by Dr. Kiyoshi Furukawa of Nagaoka
University of  Technology,  Japan.  The cells  were maintained in medium containing Dul‐
becco’s modified Eagle’s medium (DMEM; Gibco, Invitrogen Corporation, NY, USA) sup‐
plemented  with  10%  fetal  bovine  serum  (TBD;  Tianjin  Hao  Yang  Biological  Company,
Tianjin, China), 100 U/ml penicillin, and 100 μg/ml streptomycin and incubated in a hu‐
midified  (37°C,  5% CO2 and 95% air)  incubator  (Sanyo,  Toyota,  Japan).  The  cells  were
usually grown in a  60-mm culture dish (BD Falcon,  CA, USA) and passaged once they
reached  75%  confluence.  To  observe  the  effects  of  pharmacological  inhibitors  on  genes
expression,  cells  were treated with pharmacological  inhibitors  for  24 h before analyzing
genes expression by RT-PCR.
2.2. Chemicals and antibodies
LY294002 and LY303511 were purchased from Sigma-Aldrich (St. Louis, MD, USA). The
Rneasy mini kit to extract total RNA was obtained from Qiagen (Hilden, Germany). The RT-
PCR kit was from Takara Biotechnology Corporation (Dalian, China). All other reagents were
from Invitrogen (Carlsbad, CA, USA), unless otherwise specified.
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Regulation
Manner
Gene Name CSSH-1/SM-1 CAH-3/CM-1 B11/B16 Biological Functions
Positive Caveolin-1 1.378 0.321 0.146 (1)7, (4)7, (5)7
Ly-GDI 2.156 0.423 0.387 (5)8
PKN-1 1.658 0.626 0.495 (4)9
E-cadherein 1.875 0.695 0.721 (1)10, (3)11, (5)12, (6)13
Gelsolin 1.841 0.543 0.502 (4)14
MMP-9 1.915 0.174 0.282 (4)15, (5)16
MMP-2 1.532 0.534 0.472 (4)17, (5)18
Apaf1 1.350 0.608 0.509 (2)19
Rho B 2.247 0.427 0.318 (5)20, (6)20, (8)20
Midkine 1.403 0.518 0.417 (1)21
Lymphotoxin α 2.245 0.475 0.497 (6)22
Tnf α 2.188 0.349 0.292 (4)23, (5)23
Plau 1.453 0.397 0.750 (5)24, (6)24
Plaur 2.209 0.543 0.720 (2)25
Negative Integrin β5 0.783 1.465 1.754 (1)26, 27, (2)28, (3)29, (4)30
Vimentin 0.111 1.984 2.089 (7)31
TGF-β1 0.571 2.124 3.309 (1)32, (4)33, (5)33
TGFBR 2 0.716 1.453 1.903 (1)34
N-Cam 0.282 2.901 2.223 (3)35
Src 0.639 1.347 1.925 (1)36, (3)36, (4)37, (5)36
(1) Invasive Proliferation; (2) Apoptosis; (3) Adhesion; (4) Motility; (5) Invasion; (6) Metastasis; (7) Tumor marker; (8)
Transformation
Table 1. GM3 involved in regulating cancer related genes in melanoma.
2.3. RNA extraction and RT-PCR
RNA extraction and analysis of amplified DNA were described in our previous work [4], [5],
[9], [38-40]. The primers used in this study were designed with primer 3 software and synteh‐
sized by Shanghai Genebase Biotechnology Corporation (Shanghai, China). Primer sequences
used for the PCR in this study were as follows: Plau, Sense 5’-GCCCACAGA CCTGATGCTAT
and Antisense 5’-TAGAGCCTTCTGGCCACACT; Plaur, Sense 5’-AGGTGGTGACAA‐
GAGGCTGT and Antisense 5’-AGCTCTGGTCCAAAGAGGTG; gelsolin, Sense 5’-TCCAA‐
CAAGGTGCCAGTGGA and Antisense 5’- CAGCACAAAGGCATCGTTGG; Caveolin-1,
Sense 5’-CTACAAGCCCAACAACAAGGC and Antisense 5’- AGGAAGCTCTTGATG‐
CACGGT; Ly-GDI and Eef sequences are provided in our previous publications [5], [40]. The
mRNA levels of the genes under consideration, using Eef mRNA as an internal control, were
determined by RT-PCR semiquantitatively, as described previously [4, 5, 9, 38-40]. Candidate
mRNA values are expressed as a ratio of candicate mRNA to Eef mRNA and are usually
expressed as unity for control experiments.
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2.4. siRNA and cDNA constructs
Target sequences were designed and synthesized as previously described [4, 5, 9, 38-40].
Effective siRNA sequence targeting Ly-GDI can be found in our previous publications [5, 40].
For ectopic expression of Caveolin-1 or Ly-GDI, total RNA was isolated from mouse FBJ-S1
cells. After the first-strand cDNA was synthesized, a Caveolin-1 or Ly-GDI transcript was
amplified using the following sense and antisense primers: Caveolin-1, Sense 5’-GCTAG‐
CATGTCTGGGGGCAAATACGT and Antisense 5’-GGATCCTCA‐
TATCTCTTTCTGCGTGC; Ly-GDI, 5’- GCTAGCATGACGGAGAAGGATGCACAGCCA
and Antisense 5’- GGATCCTCATTCTGTCCAATCCTTCT. The coding sequence of Caveo‐
lin-1 or Ly-GDI was inserted between NheI and BamHI digestion sites for sense expression in
a pITES-puro3 expression vector with puromycin resistance (Clonetech, USA). The plasmids
were prepared and confirmed by sequencing analysis.
2.5. Transfection
In RNA interference experiments, B16 cells were transfected as previously described [4, 5, 9,
38-40]. In brief, B16 cells were transfected with Ly-GDI siRNA for 3 days and the stably
transfected cells were further selected by G418 treatment. In control experiments, cells were
transfected with scramble siRNA and also selected with G418. For ectopic expression experi‐
ments, B16 cells were transfected with Caveolin-1 or Ly-GDI cDNA contructs before analysing
the mRNA expression of corresponding genes after 3 days. Control cells were transfected with
empty vector.
3. Involvement of GM3 targeted genes in mediating melanoma metastasis
Accumulating evidence using thin-layer  chromatography techniques has shown that  the
gangliosides  GM3  and  GD3  are  predominantly  expressed  in  melanoma  cells  and  are
present in relatively higher concentrations than the more complicated gangliosides GT1,
GD1 and GM1 in adult brain tissue [41]. In line with this report, GM3 has been detected
in both human and murine melanoma cells by MAb M2590 [42], [43]. Although GM3 has
been identified several  decades  ago,  the  progress  on the  mechanism of  GM3 in  media‐
ting melanoma metastasis is slow. Prior works have shown that GM3 facilitates melano‐
ma  B16  cells  to  metastasize  in  C57BL/6  mice  [44],  [45],  but  the  mechanism  remains
unknown. In view of the complicated steps of melanoma metastasis and multiple biologi‐
cal  functions  of  GM3,  it  is  necessary  to  address  the  targets  molecules  through  which
GM3 exerts its functions on melanoma metastasis.
3.1. Ly-GDI
Ly-GDI, a Rho GTPase dissociation inhibitor beta, is also known as RhoGDI2, Arhgdib or D4-
GDI. It belongs to a family of RhoGDIs including RhoGDI1 and RhoGDI3. The family is named
for its ability to inhibit the dissociation of bound GDP from its partner Rho GTPase, which reg‐
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ulates interactions with regulatory guanine nucleotide exchange factors, GAP, and the effector
targets [46]. Among GDIs, Ly-GDI differs substantially at the structural level from the other two
GDIs and is regarded as an invasive and metastatic suppressor gene in human bladder cancer
cells [47], [48]. In line with these findings, Ota et al. [49] also reported that truncated Ly-GDI pro‐
motes metastasis of mouse colon cancer. Along with these prior works, our recent data demon‐
strate that Ly-GDI expression was positively regulated by GM3, which in turn suppresses
anchorage-independent growth in mouse melanoma B16 cells [5]. As anchorage-independent
growth has been previously regarded as one of the most important oncogenic properties of tu‐
mor cells, it is important to describe the signal transduction pathway between GM3 and Ly-
GDI, leading to suppress melanoma invasive proliferation in soft agar medium.
As a first step, we evaluated the effect of endogenous GM3 on Ly-GDI mRNA expression. Our
data reveal that Ly-GDI mRNA expression is always proportional to endogenous GM3
contents (Table. 1), which suggests possible roles of GM3 in Ly-GDI regulation. To further
confirm the notion that GM3 is responsible for Ly-GDI regulation, GM3 was exogenously
added in the culture medium of GM3-depleted cells, such as B11 clone and CAH-3 cells, as
well as B16 parental cells. Our data reveal that exogenous GM3 significantly bound to
biological membranes, which resulted in upregulation of Ly-GDI expression in three cell lines
[5]. Reciprocally, GM3 depletion was carried out by incubating cells with D-PDMP, which in
turn suppresses Ly-GDI expression. Collectively, our data demonstrated that GM3 contents
play pivotal role in regulating Ly-GDI expression [5].
To keep the discussion focused, we next aimed to characterize the signaling pathway of GM3
in regulating Ly-GDI expression. In light of the possible role of PI3-K pathway in GM3
signaling cascade [4], [40], we examined the effects of PI3-K inhibitor, LY294002, on Ly-GDI
mRNA expression in the absence or presence of GM3. Treatment of B16 and CSSH-1 cells with
LY294002 not only suppressed Ly-GDI mRNA expression, but also reversed the effects of GM3
on increasing Ly-GDI mRNA expression. Similarly, this pharmacological intervention was also
effective in suppressing Akt phosphorylation at Ser 473 and Thr 308 without altering total Akt
levels. To further exclude the possible non-specific effects of PI3-K inhibitors, we transfected
B16 cells with Akt1 or Akt2 siRNA. Our results revealed that Akt1 or Akt2 knock down
decreases Ly-GDI expression at mRNA level and the effects of suppression are more profound
in Akt1/2 doubly silenced cells. It is noteworthy that GM3 are not able to upregulate Ly-GDI
expression in Akt1/2 double knock down cells. Collectively, our results demonstrate that GM3
regulate Ly-GDI expression via PI3-K/Akt pathway [5].
Although we had found that PI3-K/Akt pathway plays pivotal role in regulating Ly-GDI
expression, the question is easily raised whether GM3 directly activates PI3-K pathway or not.
In view of the important role of Pdpk1 and mTOR complexes in PI3-K signaling cascade [50],
we determined their expression in B11 cells. Our data revealed that GM3 knock down
concurrently reduces Pdpk1 and Raptor expression, whereas induces Rictor expression.
Taking the advantage of siRNA technique, we further found that Pdpk1 and Raptor, but not
Rictor knock down abolished GM3 effects on Ly-GDI induction via blocking Akt phosphory‐
lation at Thr 308 [5]. From these observations, we demonstrate that GM3 induces Ly-GDI
expression via PI3-K, Pdpk1, AktThr308 and mTOR/Raptor pathway in melanoma B16 cells (Fig.
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1). More importantly, the experiments were also carried out to determine if Ly-GDI is the key
molecule in mediating melanoma B16 cells anchorage-independent growth. Our data dem‐
onstrate that Ly-GDI knock down significantly increased the proliferating ability of B16 cells
in soft agar or serum free medium [5]. It is noteworthy that expression of GM3 is gradually
increased during the progression of melanoma malignancy. For instance, GM3 was not
detected in normal or naevi skin, but 60% of primary and 75% of metastatic melanoma
expressed GM3 [51]. Our data along with previously published results [51] suggest that
relatively lower levels of GM3 and Ly-GDI at the early stage of melanoma facilitate melanoma
cells to undergo invasive proliferation in vigorous environment. These observations also
provide insights into the molecular basis of GM3 on augmenting melanoma invasive prolif‐
eration at the early stage of pathology.
Figure 1. Proposed cascade of GM3 signaling events in murine melanoma B16 cells metastasis. In melanoma B16 cells,
GM3 is gradually increased during the progression of melanoma malignancy and facilitates melanoma cells to meta‐
stasize. We here found that GM3 signals are transduced via PI3-K, Pdpk1, Akt and the mTOR/Raptor pathway, leading
to the expression of Ly-GDI and RhoB, which in turn suppresses mouse melanoma cell proliferation in soft agar or se‐
rum deprived medium. In addition, GM3 is able to suppress melanoma cell proliferation, adhesion, migration and in‐
vasion by inhibiting Src mRNA expression. It is noted that the above mechanisms will result in cell invasive
proliferation, migration and invasion because of relatively lower level of GM3 at early stage of melanoma progression.
In contrast, higher level of GM3 at late stage of melanoma metastasis will trigger cell migration and invasion via
MMP-2, MMP-9 and Caveolin-1 etc, although the signaling transduction pathway is the same as the above discussion.
These in vitro observations not only decipher the codes of GM3 in regulating melanoma metastasis in vivo, but also
help find new therapeutic strategies to treat melanoma disorders.
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3.2. TNF-α
TNF-α is a multifunctional cytokine, which is synthesized as a 26kDa (233 amino acids)
membrane-bound propeptide (pro-TNF-α) and is secreted upon cleavage by TNF-α convert‐
ing enzyme [52]. Studies on the effects of TNF-α using experimental models of invasion and
metastasis have shown that it can often act as a tumor promoting factor [53]. More specifically
for melanoma, TNF-α has been reported to upregulate the expression of integrin subunits,
which in turn enhance the interaction of human melanoma cells with ECM substrates [54], [55].
The more recent study from this laboratory showed that TNF-α induces integrin expression,
cell attachment and invasion via fibronectin in human melanoma cells [55]. In light of these
prior works, our recent data demonstrate that TNF-α located downstream of Ly-GDI to
mediate melanoma metastasis (Fig. 4) [4], [39], [40]. To verify that TNF-α follows the same
GM3 signaling cascade as Ly-GDI, we carried out the same experiments as above Ly-GDI. In
line with GM3 regulating Ly-GDI signaling pathway [5], our results revealed that GM3
regulates TNF-α mRNA and protein expression via PI3-K, Akt and mTOR pathway [4], [40],
suggesting that TNF-α is indeed the downstream target of Ly-GDI through which mediate
biological functions of GM3 and Ly-GDI in melanoma metastasis. Once TNF-α was found to
be a link in the chain of GM3 signaling, we focused on its biological effects on melanoma
metastasis. The results demonstrate that TNF-α is able to enhance melanoma migration via
inducing MMP-9 expression and activity [39], which will be further discussed in “MMP-9 and
MMP-2” part (Fig. 1). On the other hand, Venessa et al. [56] proposed that TNF-α protect
melanoma cells from apoptosis by BRAF inhibition. In contrast, Andrea et al. [57] reported that
TNF-α exhibited antiproliferative effects on four melanoma cell lines. In line with this report
[57], accumulating evidence demonstrates that TNF-α suppresses melanoma metastasis in
patients or murine models [58]. Although TNF-α shows its effects on suppressing melanoma
metastasis, we still could not negate its ability to induce melanoma migration and invasion.
Since the debating is still going on and the multiple biological functions of TNF-α, we are not
able to arbitrarily judge that TNF-α induces or reduces melanoma metastasis until now. It
would be finally decided by the mechanism that TNF-α predominantly exerts.
3.3. MMP-9 and MMP-2
As above discussion, TNF-α is able to enhance melanoma migration via inducing MMP-9
expression and activity [39], we next aimed to elucidate its mechanism. In order to determine
the role of MMP-9 in cell migration, we examined the effects of an MMP-9 agonist and
antagonist on cell migration, as stimulation of MMP-9 expression by TNF-α has been reported
in several studies [59], [60]. We therefore used TNF-α as a positive control against the MMP-9
inhibitor GM6001. RT-PCR results demonstrate that TNF-α markedly induces MMP-9
expression and activity, which is reversed by GM6001 treatment [39]. Furthermore, cell
migration tested by transwell experiments showed that the numbers of cells migrating were
consistent with MMP-9 expression [39]. This finding is in accordance with previously pub‐
lished data showing that TNF-α increases human melanoma cell invasion and migration in
vitro, whereas they could not further extend their investigation to MMP-9 [23]. Bianchini et
al. [59] proceed to find that invasive phenotype of murine melanoma cells stimulated with
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TNF-α was characterized by an enhanced MMP-9 expression. More importantly, we extended
their investigations to GM3 and further reveal that GM3 also regulate MMP-9 expression and
activity via PI3-K, Akt, Ly-GDI and TNF-α pathway [39]. Therefore, our findings [39] along
with the prior works [23], [59] demonstrate that TNF-α induces melanoma migration and
invasion via augmenting MMP-9 expression.
In addition to MMP-9, it is noteworthy that MMP-2 is also induced by endogenous GM3 (Table.
1). Although we are still not figure out the mechanism that GM3 positively regulates MMP-2
expression in melanoma B16 cells, MMP-2 has been implicated to be associated with progres‐
sion of the melanoma [61]. In more detail, although all skin and nodal metastasis were negative
for MMP-2, higher MMP-2 concentrations were observed in patients with metastatic disease
(stage IV) than in those with primary melanoma (stage I) or in controls [61]. In addition, Liu
et al. [62] recently published research showing that d-GM3, a derivative of ganglioside GM3,
stimulates melanoma cell migration and invasion by increasing the expression and activation
of MMP-2. To keep the discussion focused, it should be also noted that expression of GM3 is
gradually increased during the progression of melanoma malignancy [51]. Once GM3 was
markedly induced at the late stage of melanoma, MMP-9 and MMP-2 would be activated by
GM3, which in turn mediating migration and invasion in melanoma progression. Therefore,
multiple biological functions and stage dependent expression manner of GM3 make it possible
to induce invasive proliferation of melanoma at early stage and stimulate melanoma cell
migration and invasion at late stage of melanoma progression (Fig.1).
3.4. Plau and Plaur
During the course of MMP-9 and MMP-2 investigations, experimental evidence had led to the
recognition of Plau and Plaur [59], [62]. Indeed, Plau and Plaur are highly expressed in
advanced stages of primary and metastatic melanoma progression [63]. In addition, Bianchini
et al. [59] proposed that costimulation with TNF-α and IFNγ enhancing murine melanoma B16
cells metastasis via inducing Plaur mRNA and protein expression. Moreover, Liu et al. [62]
extended the above findings to exogenous d-GM3 treatment, the results suggested that d-GM3
promotes melanoma cell migration and invasion through Plaur signaling dependent pathway,
which in turn mediating melanoma cell migration and invasion via MMP-2. Along with these
prior works [59], [62], our data revealed that endogenous GM3 is able to positively regulate
Plau and Plaur mRNA expression in mouse melanoma B16 cells (Table. 1). Although the
mechanism that GM3 regulates Plau and Plaur mRNA expression is still going on in our lab,
we already found that PI3-K/Akt pathway plays key roles in regulating Plau and Plaur mRNA
expression in B16 cells (Fig. 2). To elucidate the biological functions of Plau and Plaur, Bianchini
et al. [59] already found that Plaur monoclonal antibody treatment caused a significant
reduction of invasiveness in TNF-α/IFNγ stimulated melanoma cells. In addition, targeting
Plaur has practical implications in treating cancer. For example, 1) downregulating Plaur
expression leads to dormancy of cancer cells [64]; 2) administrating Plaur antagonists markedly
inhibits metastatic ability, including that of melanomas [65]; 3)deficiency of plasminogen/Plau
in mice slows tumor growth and progression [65]; and 4) inhibiting Plau and/or its binding
with Plaur prevents metastasis in animal models [66]. Collectively, the additional role of Plau/
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Plaur signaling in mediating GM3 function [67] makes Plau/Plaur system as an attractive target
for cancer therapy.
Figure 2. Involvement of PI3-K signaling pathway in Plau and Plaur synthesis in mouse melanoma B16 cells. B16 (A-D)
or CSSH-1 (B-D) cells were incubated with either LY294002, LY303511 or Wortmannin for the indicated concentra‐
tions. Plau (A) and Plaur (B-D) mRNA expressions were determined by RT-PCR after 24h incubation. Eef served as inter‐
nal control. The intensity of bands was analyzed relative to Eef for each treatment using the Bio-Profile Bio ID gel
image system at 312nm.
3.5. Gelsolin
Gelsolin is a representative actin-regulatory protein with an 82kDa mass and is present in most
vertebrate tissues. Gelsolin controls the length of actin polymers in vitro by a variety of
mechanisms [68], [69]. Since actin filament reorganization is important for cell shape and
motility, gelsolin has crucial roles in the control of these cellular functions [70], [71]. Accumu‐
lating evidence has shown that gelsolin expression is frequently downregulated in several
types of human cancers, such as gastric, bladder, colon and lung [72]- [75]. In addition, ectopic
expression of wild-type gelsolin resulted in suppression of tumorigenicity of both bladder and
colon carcinoma cell lines [73], [76]. However, a new 85kDa truncated gelsolin (GSNp85), co-
expressed with wild-type gelsolin, was frequently expressed in vertical growth phase mela‐
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nomas (Clark level II-IV) and metastatic growth phase melanomas [77]. Moreover, Litwin et
al. [78] recently found that downregulation of gelsolin expression in melanoma A375 cells
significantly reduce their migratory potential. These disparate observations might be attrib‐
uted to different species of cancer cells. Consistent with the prior works [77], [78], we newly
found that endogenous GM3 has ability to regulate gelsolin mRNA expression (Table. 1). In
addition, PI3-K/Akt signaling pathway was found to exert critical role in mediating gelsolin
mRNA induction (Fig. 3A). Moreover, gelsolin is found to be downstream targets of Ly-GDI
in melanoma B16 cells by the experiments of Ly-GDI knock down (Fig. 3B). This observation
not only demonstrates the critical role of Ly-GDI, but also provides new insights in melanoma
metastasis (Fig. 1). More importantly, it is also indicating that alterations in the expression level
of gelsolin and its subcellular distribution may be directly responsible for determining
migration capacity of melanoma.
Figure 3. Involvement of PI3-K signaling pathway in gelsolin synthesis in mouse melanoma B16 cells. B16 (A, left pan‐
el) or CSSH-1 (A, right panel) cells were incubated with either LY294002 (25 μM) or Wortmannin (1 μM) for 24 h. In
selected experiments, B16 cells were transfected with Ly-GDI siRNA and further established Ly-GDI knocking down cell
lines by G418 selection (B). Gelsolin mRNA expression was determined by RT-PCR after 24h incubation. Eef served as
internal control. The intensity of bands was analyzed relative to Eef for each treatment using the Bio-Profile Bio ID gel
image system at 312nm.
3.6. Caveolin-1
Caveolin-1 is a 22-24 KDa protein originally identified as a structural component of caveolae,
specialized invagination of the plasma membrane. These caveolae represent compartments in
which key signaling transduction molecules are concentrated to provide an efficient system
for cellular cross talk. However, relatively little information is available concerning the role of
Caveolin-1 in melanomas. Early studies demonstrate that increased Caveolin-1 expression was
associated with enhanced malignancy in a non-cutaneous, retinal melanoma [79]. An even
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more recent study identified exosomes in the plasma of melanoma patients with high levels
of Caveolin-1.In this particular case, exosomes are associated with malignant tumor progres‐
sion as a small vesicle secreted by both normal and tumoral cells [80]. These prior works
demonstrate that Caveolin-1 are relevant to function in melanoma metastasis.
Additional studies support the notion that presence of Caveolin-1 helps melanoma metastasis.
Felicetti et al. proposed that Caveolin-1 expression is associated with increased metastatic po‐
tential in different human melanoma cell lines. Specifically, Caveolin-1 expression increased
cell proliferation, anchorage-independent growth, migration and invasion in WM983A mela‐
noma cell line. Alternatively, Caveolin-1 down-regulation in metastatic Caveolin-1 overex‐
pressing melanomas reduces their proliferation, as well as their tumorigenicity [7]. Consistent
with prior works [7], we further found that Caveolin-1 was regulated by endogenous GM3 (Ta‐
ble. 1). More importantly, our recent data revealed that Caveolin-1 is able to regulate TNF-α
(Fig. 4), which in turn mediates melanoma migration or invasion through MMP-9 as discussed
above [39]. Our data along with previous reports [7] further implicated the important role of
GM3-enriched membrane subdomain, especially Caveolae, in melanoma metastasis.
Figure 4. Ly-GDI overexpression induces TNF-α mRNA expression in mouse melanoma B16 cells. B16 or Ly-GDI knock‐
ing down cells were transfected with Ly-GDI or Caveolin-1 cDNA construct. Ly-GDI, TNF-α and Caveolin-1 mRNA ex‐
pressions were determined by RT-PCR after 3 days transfection. Eef served as internal control. The intensity of bands
was analyzed relative to Eef for each treatment using the Bio-Profile Bio ID gel image system at 312nm.
3.7. Src
Over the past few decades, studies of Src and the SFKs have given new insights into the role
of these proteins in regulating cell adhesion, invasiveness and motility in cancer cells and in
tumor vasculature, rather than directly influencing cell proliferation [81]. Src expression and
activity are increased in melanoma cell lines and in melanoma tumors in vivo [82]. Src activity
was detected in the following cell lines: LOX, IMVI, MALME-3M, SK-MEL-2, SK-MEL-5, SK-
MEL-28, M19-MEL, UACC-62 and UACC-257. The highest activity was that in the M14
melanoma cell lines.
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Src can activate STAT3, STAT5 and other downstream targets in melanoma [83]. The expres‐
sion of STAT3 is highly expressed in both primary and metastatic melanoma in humans,
although the expression level is variable [81]. In addition, STAT3 is activated in human
melanoma, but not in melanocytic or in benign melanocytic neoplasms [84]. Moreover,
blocking STAT3 signaling in mouse B16 melanoma cells resulted in the release of soluble
factors capable of inducing apoptosis and cell-cycle arrest [85]. In vivo, inerfering with STAT3
signaling suppressed growth of syngeneic murine melanoma B16 tumor [86]. In addition to
STAT3, it was recently found that STAT5 signaling in melanoma cell lines is mediated by the
EGFR tyrosine kinase and by intracellular non-receptor tyrosine kinase, such as Src and JAK1.
The expression of STAT5 is increased in melanoma metastasis compared with normal human
melanocytes and STAT5 is activated in 62% of human melanoma metastasis. Alternatively,
inhibiting STAT5 expression significantly reduced the expression of Bcl-2 and decreased cell
viability and increased apoptosis in the melanoma cell lines. In view of the critical role of Src
in melanoma invasive proliferation, we further found that Src was negatively regulated by
endogenous GM3 (Table.1). This result along with previous reports [51], [83]- [86] indicated
that GM3 regulates melanoma invasive proliferation via Src at the early stage of melanoma or
at the stage of transformation, but not in advanced stage of melanoma (Fig. 1). Although we
haven’t found detailed mechanism that GM3 regulates Src mRNA expression, which in turn
resulting in melanoma metastasis, it is still noteworthy to emphasize that Src mediated
melanoma invasive proliferation might be the pivotal mechanism, which mediates melanoma
transformation or onset of disease at the early stage when GM3 expression is still relative low.
Therefore, it is also important to elucidate the biological function of Src when the expression
is still low at the early stage of melanoma progression. These future discoveries will make us
understand which mechanism predominantly contributed to the metastasis progression of
melanoma at different stages or at different steps of cancer metastasis.
3.8. Rho B
Recent  studies  confirmed  the  role  of  the  Rho  proteins  in  cancer  by  showing  their  in‐
volvement in cell transforamtion, invasion, metastasis and angiogenesis. The major mem‐
bers  of  the  Rho  subfamily  comprise  the  Rho  A,  Rho  B  and  Rho  C  proteins.  Rho  B  is
quite different from Rho A and Rho C in many aspects, although it shares 87% homolo‐
gy [20].  For example, Rho B has a tumor suppressive role,  including inhibiting cell  pro‐
liferation  and  inducing  apoptosis  in  several  human  cancer  cells,  and  inhibiting  tumor
growth in murine model, in contrast, activation of Rho A promotes cell malignant trans‐
formation,  proliferation,  invasion and metastasis,  like  other  small  GTPases  such as  Ras,
Rac1 and Cdc42 [87] Moreover,  Rho B, unlike the constitutively expressed Rho A, is in‐
ducible by genotoxic stress, such as U.V. light, growth factors (TGF-β1) and chemothera‐
peutic  drugs  (cisplatin  and  5-FU).  In  our  experimental  system,  we  found  that  mRNA
expression of Rho B is suppressed by Ly-GDI knocking down [5]. This observation parti‐
ally  implied that  Rho B located downstream of  Ly-GDI to  mediate  its  inhibitory effects
on  melanoma  invasive  proliferation  and  would  also  exerts  its  effects  at  early  stage  of
melanoma progression (Fig. 1).
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3.9. Other genes
During  the  course  of  our  investigation  in  melanoma  metastasis,  we  also  found  the  in‐
volvement of  some pro-oncogenes or  tumor suppressor  genes,  such as  TGF-β1,  N-Cam,
integrin β5, PKN1 or E-cadherin et al.,  (Table. 1) in GM3 biological functions to mediate
melanoma  cells  invasive  proliferation,  adhesion,  migration  and  invasion,  which  finally
contribute to melanoma transformation and progression. Although these steps of melano‐
ma  metastasis  are  not  separate,  our  in  vitro  experiments  have  partially  revealed  the
mechanism  of  melanoma  metastasis  at  different  stages.  More  importantly,  deciphering
the mechanism of GM3 in mediating melanoma metastasis will  help find new therapeu‐
tic strategies to treat melanoma disorders.
4. Conclusion
Metastasis, the spread of malignant tumor cells from a primary site to distant sites, is the
most  life-threatening  complication  of  cancer  and  a  major  problem  of  cancer  treatment
[88],  [89].  The  metastatic  process  consists  of  multiple  steps:  1)  invasive  proliferation  as
benign tumor  at  the  primary  site  2)  dissociation  of  tumor  cell(s)  from the  primary  site
with  a  concomitant  loss  of  cell-cell  and  cell-ECM  adhesions;  3)  tumor-cell  adhesion  to
and subsequent  local  digestion of  basement membrane;  4)  retraction of  endothelial  cells
and  subsequent  intravasation;  5)  survival  within  the  vasculature;  6)  extravasation  from
vasculature at a distinct site and 7) growth in a “foreign” or ectopic organ environment
[90], [91]. In view of these prior theories, our data summarized here reinforce the notion
that GM3 potentially plays a dual role in melanoma development, as has been described
in  our  previously  published  works4-6,  [39],  [92].  At  early  stage  of  melanoma  metastasis,
lower level of GM3 induces melanoma invasive proliferation via Src, Rho B and Ly-GDI
et  al.  Alternatively,  higher  levels  of  GM3 at  the  late  stage of  melanoma metastasis  trig‐
gers  cell  migration and invasion via  MMP-2,  MMP-9 and Caveolin-1  etc.  These  in  vitro
observations not  only decipher the codes of  GM3 in regulating melanoma metastasis  in
vivo, but also help find new therapeutic strategies to treat melanoma disorders.
Nomenclature
GSLs, sialylated glycosphingolipids; RTK, receptor tyrosine kinase; PI3-K, phosphatidylino‐
sitol-3-kinase; Rb, retinoblastoma; PKN1, protein kinase 1; MMP-9, matrix matelloprotei‐
nase-9; MMP-2, matrix metalloproteinase-2; Apaf1, apoptotic protease activating factor 1;
TNF-α, tumor necrosis factor-α; Plau, urokinase-type plasminogen activator; Plaur, urokinase-
type plasminogen activator receptor; TGF-β1, transforming growth factor-β1; TGFBR2,
transforming growth factor, beta receptor 2; RhoGDI, RhoGDP dissociation inhibitors; GAP,
GTPase-activating proteins; Pdpk1, 3-phosphoinositide dependent protein kinase-1; mTOR,
mammalian target of rapamycin; Raptor, regulatory associated protein of mTOR; ECM,
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extracellular matrix; d-GM3, De-N-acetyl GM3; IFNγ, interferon γ; SFKs, Src-family kinases;
STAT3, signal transducer and activator of transcription 3; STAT5, signal transducer and
activator of transcription 5; JAK1, Janus kinase 1.
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